| Drug Name |
Cidofovir dihydrate |
| Drug ID |
BADD_D00464 |
| Description |
Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. It suppresses CMV replication through selective inhibition of viral DNA synthesis.[FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223] |
| Indications and Usage |
For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) |
| Marketing Status |
approved |
| ATC Code |
J05AB12 |
| DrugBank ID |
DB00369
|
| KEGG ID |
D00273
|
| MeSH ID |
D000077404
|
| PubChem ID |
60933
|
| TTD Drug ID |
D04AAW
|
| NDC Product Code |
14593-840; 71052-483; 73309-228; 82891-006; 82772-002; 23155-216; 73377-064 |
| UNII |
JIL713Q00N
|
| Synonyms |
Cidofovir | HPMPC | GS 504 | GS-504 | GS504 | Cidofovir, Sodium Salt | Cidofovir Sodium | Cidofovir, (R)-isomer | Cidofovir Anhydrous | 1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine | 1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine | Vistide | Cidofovir, (+-)-isomer |
